P27单克隆抗体
包装与价格:
产品名称 CDKN1B/p27 KIP 1 Mouse mAb 产品介绍
P27单克隆抗体 商品属性
中文名称P27单克隆抗体 别 名p27 KIP 1; CDN1B_HUMAN; AA408329; AI843786; Cdki1b; CDKN 1B; CDKN 4; CDKN1B; CDKN1B; CDKN4; CDKN4; Cyclin Dependent Kinase Inhibitor 1B; Cyclin Dependent Kinase Inhibitor 1B; Cyclin dependent kinase inhibitor p27; Cyclin dependent kinase inhibitor p27; Cyclin-dependent kinase inhibitor 1B(p27, Kip1); Cyclin-dependent kinase inhibitor 1B; Cyclin-dependent kinase inhibitor p27; Cyclin-dependent kinase inhibitor p27 Kip1; KIP 1; KIP1; MEN1B; MEN4; OTTHUMP00000195098; OTTHUMP00000195099; p27; p27 Kip1; P27-like cyclin-dependent kinase inhibitor; P27KIP1. 研究领域肿瘤 免疫学 染色质和核信号 信号转导 细胞凋亡 抗体来源Mouse 克隆类型Monoclonal 克 隆 号1A7 交叉反应Human 产品应用IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. 理论分子量22 kDa 检测分子量 细胞定位细胞核 细胞浆 性 状Liquid 浓 度1mg/ml 免 疫 原Recombinant human CDKN1B 亚 型IgG1 纯化方法affinity purified by Protein A 缓 冲 液0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. 保存条件Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. 注意事项This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. PubMedPubMed 产品介绍Cell cycle progression is regulated by cyclins and their cognate Cdks. p27 KIP 1 is a cell cycle regulatory mitotic inhibitor of cdk activity. p27 KIP 1 is a candidate tumor suppressor gene, and has been proposed to function as a possible mediator of TGF beta induced G1 arrest. p27 KIP 1 is up regulated in response to antimitogenic stimuli. The increased protein expression of p27 results in cellular arrest by binding to cyclin/Cdk complexes such as cyclin D1/Cdk4. p27 Kip1 is regulated by phosphorylation on serine 10 (S10) and threonine 187 (T187). Phosphorylation by CDK2 on T187 results in ubiquitylation and degradation of p27 Kip 1; while phosphorylation by hKIS on S10 signals the nuclear export to the cytoplasm. 靶点与功能
P27(CDKN1B/Kip1)是定位于12p13染色体的抑癌基因,通过竞争性结合cyclin-CDK复合物(如cyclin E-CDK2、cyclin D-CDK4),抑制其激酶活性,从而阻断细胞从G1期向S期转换,实现细胞周期停滞。其表达下调或缺失常见于乳腺癌(60%)、肺癌(55%)、胃癌(45%) 等恶性肿瘤,是判断肿瘤侵袭性和患者预后的重要标志物。 实验操作关键要点
WB优化(肿瘤细胞系检测): 样本处理:使用含1mM PMSF和磷酸酶抑制剂的RIPA裂解液,冰上裂解30分钟,12000g离心15分钟取上清,避免P27降解(半衰期约2小时); 电泳条件:12% SDS-PAGE凝胶,恒压80V浓缩胶、120V分离胶,转膜选用0.45μm PVDF膜(250mA恒流1.5小时); 抗体孵育:小鼠单抗推荐1:500稀释(5% BSA+TBST),4℃缓慢摇动过夜;兔单抗1:2000稀释,室温孵育2小时,二抗(HRP标记)1:5000室温孵育1小时。 IHC-P注意事项(临床肿瘤组织): 抗原修复:采用柠檬酸钠缓冲液(pH6.0) 微波修复20分钟(95℃),增强核/质信号; 阳性定位:正常组织中胞核/胞质呈强阳性,肿瘤组织中因降解或核输出呈低表达(可与Ki-67共染验证细胞增殖活性); 对照设置:必须包含正常乳腺/肺组织(阳性对照)和P27敲除细胞系(阴性对照)。 IP实验关键步骤: 抗体用量:2μg抗体/500μg总蛋白,4℃旋转孵育4小时; Beads选择:Protein A/G磁珠,预洗3次后与抗体-抗原复合物孵育2小时; 洗脱与检测:5×SDS上样缓冲液100℃煮沸5分钟,搭配cyclin E或CDK2抗体检测相互作用。 公司正在出售的产品
用户评论 产品评分 目前评分共0人 产品质量
售后服务
易用性
性价比
|
相关产品:
|